129 related articles for article (PubMed ID: 35080473)
1. Changes in intracellular activation-related gene expression and induction of Akt contribute to acquired resistance toward nelarabine in CCRF-CEM cell line.
Rindiarti A; Okamoto Y; Nakagawa S; Hirose J; Kodama Y; Nishikawa T; Kawano Y
Leuk Lymphoma; 2022 Feb; 63(2):404-415. PubMed ID: 35080473
[TBL] [Abstract][Full Text] [Related]
2. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
3. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
[TBL] [Abstract][Full Text] [Related]
4. Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
BMC Cancer; 2014 Jul; 14():547. PubMed ID: 25070259
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
Yoshida K; Fujita A; Narazaki H; Asano T; Itoh Y
Cancer Chemother Pharmacol; 2022 Jan; 89(1):83-91. PubMed ID: 34825941
[TBL] [Abstract][Full Text] [Related]
6. Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.
Sripornsawan P; Okamoto Y; Nishikawa T; Kodama Y; Yamaki Y; Kurauchi K; Tanabe T; Nakagawa S; Shinkoda Y; Imuta N; Kawano Y
Pediatr Blood Cancer; 2017 Feb; 64(2):250-253. PubMed ID: 27576612
[TBL] [Abstract][Full Text] [Related]
7. Grape seed proanthocyanidin extract reverses multidrug resistance in HL-60/ADR cells via inhibition of the PI3K/Akt signaling pathway.
Lin KN; Jiang YL; Zhang SG; Huang SY; Li H
Biomed Pharmacother; 2020 May; 125():109885. PubMed ID: 32007917
[TBL] [Abstract][Full Text] [Related]
8. Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias.
Beck JF; Brügger D; Brischwein K; Liu C; Bader P; Niethammer D; Gekeler V
Jpn J Cancer Res; 2001 Aug; 92(8):896-903. PubMed ID: 11509123
[TBL] [Abstract][Full Text] [Related]
9. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T
Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines.
Nuessler V; Stötzer O; Gullis E; Pelka-Fleischer R; Pogrebniak A; Gieseler F; Wilmanns W
Leukemia; 1999 Nov; 13(11):1864-72. PubMed ID: 10557064
[TBL] [Abstract][Full Text] [Related]
12. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
[TBL] [Abstract][Full Text] [Related]
13. Radiation and heat sensitivity of human T-lineage acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML) clones displaying multiple drug resistance (MDR).
Uckun FM; Mitchell JB; Obuz V; Chandan-Langlie M; Min WS; Haissig S; Song CW
Int J Radiat Oncol Biol Phys; 1992; 23(1):115-25. PubMed ID: 1572809
[TBL] [Abstract][Full Text] [Related]
14. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
DeAngelo DJ
Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
[TBL] [Abstract][Full Text] [Related]
15. Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway.
Yuan R; Chang J; He J
Cell Mol Biol (Noisy-le-grand); 2020 Sep; 66(6):81-85. PubMed ID: 33040790
[TBL] [Abstract][Full Text] [Related]
16. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
[TBL] [Abstract][Full Text] [Related]
18. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
20. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
